Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled by Its Hybrozyme™ Technology
DAEJEON, South Korea–(BUSINESS WIRE)–#ALTB4—Alteogen Inc. (KOSDAQ:196170) announced today that it has entered into an exclusive license agreement with Intas Pharmaceuticals…